|
|
|
| Study on the clinical effect and mechanism of Shugan Huazhuo Decoction in treating diabetes mellitus complicated with nonalcoholic fatty liver disease |
| LI Yue MIAO Qiuli ZHANG Wenrui▲ |
| Department of Pharmacy, the First Hospital of Jilin University, Jilin Province, Changchun 130021, China |
|
|
|
Abstract Objective To observe the clinical effect of Shugan Huazhuo Decoction on patients with diabetes mellitus combined with nonalcoholic fatty liver disease (NAFLD), in order to study its mechanism. Methods From June 2015 to January 2017, 80 patients with diabetes mellitus combined with NAFLD treated in the First Hospital of Jilin University were selected and divided into control group and observation group by random number table, with 40 cases in each group. The control group was treated with Polyene Phosphatidylcholine Capsule, while the observation group was treated with Polyene Phosph atidy leholine Capsule Shugan Huazhuo Decoction. The liver function, lipid metabolism and insulin resistance in the two groups were compared. Results After treatment, the levels of aspartate aminotransferase, alanine aminotransferase, glutamyl transpeptidase, transforming growth factor-β1 (TGF-β1), total cholesterol triglyceride, low density lipoprotein cholesterol (LDL-C), fasting insulin and insulin resistance index (HOMA-IR) were significantly decreased, with statistically significant difference (P < 0.05). Compared with the control group after treatment, except for the levels of LDL-C and fasting blood glucose (FPG), the other indexes in the observation group were significantly lower, with statistically significant difference (P < 0.05). The effective rate of the observation group was significantly higher than that of the control group, with statistically significant difference (P < 0.05). Conclusion The clinical effect of Shugan Huazhuo Decoction on patients with diabetes mellitus combined with NAFLD is accurate, and its mechanism may be related to improve blood lipid metabolism, reduce insulin resistance.
|
|
|
|
|
|
[1] 周恒，李俊，王华.酒精性肝病动物模型研究进展[J].中国药理学通报，2016，32（4）：468-472.
[2] Alisi A，Cianfarani S，Manco M，et al． Non-alcoholic fatty liverdisease and metabolic syndrome in adolescents： pathogenetic role ofgenetic background and intrauterine environment [J]. Ann Med，2012，44：29-40.
[3] 董姝，刘平，孙明瑜.非酒精性脂肪肝发病机制——二次打击学说研究进展[J].临床肝胆病杂志，2012，28（7）：551-555.
[4] 全晓红，李秀丽，叶冬梅，等.非酒精性脂肪肝患者血清抵抗素与胰岛素抵抗关系研究[J].中华实用诊断与治疗杂志，2015，29（4）：372-374.
[5] 翁思颖，柴可夫，周建扬. 2型糖尿病合并非酒精性脂肪肝中医体质分布规律与基因多态性关系研究[J].中华中医药杂志，2017，32（5）：2216-2219.
[6] 潘雨亭，许方圆，于希忠，等.中药活性成分治疗非酒精性脂肪肝作用靶点的研究进展[J].中国中药杂志，2017， 42 （6） ：1109-1112.
[7] 吴丽，张峰，郑仕中，等.中医药治疗非酒精性脂肪肝的研究进展[J].中成药，2015，5（37）：1072-1075.
[8] 乐琦琦，刘晏.非酒精性脂肪肝的临床和药理研究进展[J].中成药，2014，36 （2） ：371-376.
[9] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南（2010年修订版）[J].中华肝脏病杂志，2010，18（3）：43-48.
[10] 陆菊明.从2015美国糖尿病协会《糖尿病医学诊疗标准》看降糖药物治疗新进展[J].临床药物治疗杂志，2015， 13（4）：1-4.
[11] 郑筱萸.中药新药临床研究指导原则（试行）[S].北京：中国医药科技出版社，2002.
[12] 陈思，赵金珍，胡晶，等.他汀类药物在治疗非酒精性脂肪肝病中的研究进展[J].中国动脉硬化杂志，2017，25（3）：297-303.
[13] 樊冬梅，曾燕静，吴咏梅，等.肝脾相关理论干预非酒精性脂肪肝肝纤维化的临床研究[J].时珍国医国药，2012， 23（11） ：2846-2847.
[14] 周显华，张传涛，郑政隆，等.加味楂曲饮治疗非酒精性脂肪肝的临床疗效及机制研究[J].中国实验方剂学杂志，2013，19（5） ：285-288.
[15] 许勇，陶颖，苟小军.非酒精性脂肪肝中医病因病机探析[J].中华中医药学刊，2016，32（11）：2586-2589.
[16] 王素美，曹永仓，赵娟，等.健脾疏肝颗粒对链脲佐菌素所致糖尿病小鼠的抗糖尿病效应及其作用机制的研究[J].中国医院药学杂志，2017，37（4）：348-351.
[17] 汤智慧，蔡乐，李久旭，等.胰高血糖素样肽1受体激动剂治疗2型糖尿病合并非酒精性脂肪肝有效性的系统评价和Meta分析[J].中国药学杂志，2017，52（6）：500-505.
[18] 方波，齐峰，张玉立，等.疏肝化浊降糖方对2型糖尿病胰岛素敏感性的影响[J].中国实验方剂学杂志，2014， 20（8）：218-221.
[19] 周小俐，李东风，徐丽姝. GLP-1对非酒精性脂肪肝病大鼠胰岛素抵抗及PKCε的影响[J].中国病理生理杂志，2015，31（4）：690-694.
[20] 朱升龙，张振宇，任桂萍，等. FGF21对MSG胰岛素抵抗小鼠的非酒精性脂肪肝的治疗作用及其机制研究[J].药学学报，2013，4（12）：1778-1784. |
|
|
|
